Publication:
Changes in the epidemiological landscape of invasive mould infections and disease

dc.contributor.authorLass-Flörl, Cornelia
dc.contributor.authorCuenca-Estrella, Manuel
dc.contributor.funderBasilea Pharmaceutica International
dc.date.accessioned2019-02-27T18:46:42Z
dc.date.available2019-02-27T18:46:42Z
dc.date.issued2017-03
dc.description.abstractAlthough a wide variety of pathogens are associated with invasive mould diseases, Aspergillus spp. have historically been one of the most common causative organisms. Most invasive mould infections are caused by members of the Aspergillus fumigatus species complex and an emerging issue is the occurrence of azole resistance in A. fumigatus, with resistance to amphotericin B documented in other Aspergillus spp. The epidemiology of invasive fungal disease has shifted in recent years as non-A. fumigatus Aspergillus spp. and other moulds have become progressively more important, although there are no consolidated data on the prevalence of less common species of moulds. The incidence of mucormycosis may have been underestimated, which is a potential concern since species belonging to the order Mucorales are more resistant to antifungal agents than Aspergillus spp. All species of Mucorales are unaffected by voriconazole and most show moderate resistance in vitro to echinocandins. Fusarium spp. may be the second most common nosocomial fungal pathogen after Aspergillus in some tertiary hospitals, and show a susceptibility profile marked by a higher level of resistance than that of Aspergillus spp. Recently, Scedosporium aurantiacum has been reported as an emerging opportunistic pathogen, against which voriconazole is the most active antifungal agent. Other mould species can infect humans, although invasive fungal disease occurs less frequently. Since uncommon mould species exhibit individual susceptibility profiles and require tailored clinical management, accurate classification at species level of the aetiological agent in any invasive fungal disease should be regarded as the standard of care.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis Supplement was funded by Basilea Pharmaceutica International Ltd, Basel, Switzerland.es_ES
dc.format.numbersuppl_1es_ES
dc.format.pagei5-i11es_ES
dc.format.volume72es_ES
dc.identifier.citationJ Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i5-i11.es_ES
dc.identifier.doi10.1093/jac/dkx028es_ES
dc.identifier.e-issn1460-2091es_ES
dc.identifier.issn0305-7453es_ES
dc.identifier.journalThe Journal of antimicrobial chemotherapyes_ES
dc.identifier.pubmedID28355462es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7247
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.relation.publisherversionhttps://doi.org/10.1093/jac/dkx028es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-SinObraDerivada 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAntifungal Agentses_ES
dc.subject.meshAspergillosises_ES
dc.subject.meshAspergillus fumigatuses_ES
dc.subject.meshDrug Resistance, Fungales_ES
dc.subject.meshFusariosises_ES
dc.subject.meshFusariumes_ES
dc.subject.meshHumanses_ES
dc.subject.meshImmunocompromised Hostes_ES
dc.subject.meshInvasive Fungal Infectionses_ES
dc.subject.meshMucoraleses_ES
dc.subject.meshMucormycosises_ES
dc.subject.meshScedosporiumes_ES
dc.titleChanges in the epidemiological landscape of invasive mould infections and diseasees_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication97aa0ff7-7128-4c03-a014-1200e997c819
relation.isAuthorOfPublication.latestForDiscovery97aa0ff7-7128-4c03-a014-1200e997c819

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ChangesInTheEpidemiological_2017.pdf
Size:
216.11 KB
Format:
Adobe Portable Document Format
Description: